Search
Indacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIt was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler.
Bimatoprost
go.drugbank.com/drugs/DB00905ApprovedInvestigationalBimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution an...
Marnetegragene autotemcel
go.drugbank.com/drugs/DB17595ApprovedThese modified cells differentiate to express functional CD18 protein, restoring leukocyte adhesion and extravasation.
Non-venereal endemic syphilis
go.drugbank.com/conditions/DBCOND0025727Drugs: Procaine benzylpenicillinSynonyms: BejelMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigationalMirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound D...
Agalsidase alfa
go.drugbank.com/drugs/DB15874ApprovedInvestigational[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.
Lutetium Lu 177 dotatate
go.drugbank.com/drugs/DB13985ApprovedInvestigationalCompared to the alternative somatostatin analogue DOTA-Tyr3-octreotide (dotatoc), Lutetium Lu 177 dotatate displays higher uptake of radioactivity in tumors and better residence times [A31696]. … to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed
NP2
go.drugbank.com/drugs/DB06308InvestigationalNP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin.
Levomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigational[L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.[L48011]